Christine M. Walko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christine M. Walko has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Todd C. Knepper
Moffitt Cancer Center, DeBartolo Family Personalized Medicine Institute, Tampa, FL, USA
4 shared publications - Daniel Louis Hertz
Department of Clinical Pharmacy University of Michigan College of Pharmacy Ann Arbor Michigan USA
2 shared publications - Donald M Smith
MedStar Health Columbia Maryland USA
2 shared publications Howard L. McLeod
Moffitt Cancer Center, Tampa, FL
2 shared publications- Ibrahim Halil Sahin
University of Michigan, Ann Arbor, United States, USA
2 shared publications - James Kevin Hicks
Department of Pathology, Moffitt Cancer Center, Tampa, FL
2 shared publications
Latest Publications
- Open Access
- 9 November 2026
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 12 (19)
Intracranial EWSR1::CREM fusion sarcoma presenting as a paraneoplastic inflammatory syndrome: illustrative case
BACKGROUND: Intracranial mesenchymal tumors with EWSR1::CREM fusion are rare neoplasms that can mimic common dural-based lesions like meningiomas and may present with atypical systemic features driven by tumor-associated inflammatory signaling. OBSERVATIONS: The authors report the case of a 31-year-old female who initially presented with unexplained anemia, systemic inflammatory symptoms, and difficulties with conception. Despite extensive hematological and rheumatological evaluation, no unifying diagnosis was identified. Imaging ultimately revealed a right frontal dural-based mass initially suspected to represent meningioma. She underwent gross-total resection, and pathological analysis demonstrated a high-grade sarcoma with EWSR1::CREM fusion. Notably, her systemic symptoms resolved completely following tumor removal, and the patient conceived approximately 1 month after resection. LESSONS: This case illustrates a rare intracranial EWSR1::CREM -fused tumor presenting with a paraneoplastic inflammatory syndrome that may have impaired conception in a reproduction-aged female. These lesions can radiographically mimic benign dural-based tumors such as meningioma while producing systemic inflammatory effects. Accurate diagnosis is critical, as tumor-directed therapy may result in resolution of both systemic symptoms and associated reproductive dysfunction. https://thejns.org/doi/10.3171/CASE26694
- 9 November 2026
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 12 (19)
Open AccessIntracranial EWSR1::CREM fusion sarcoma presenting as a paraneoplastic inflammatory syndrome: illustrative case
BACKGROUND: Intracranial mesenchymal tumors with EWSR1::CREM fusion are rare neoplasms that can mimic common dural-based lesions like meningiomas and may present with atypical systemic features driven by tumor-associated inflammatory signaling. OBSERVATIONS: The authors report the case of a 31-year-old female who initially presented with unexplained anemia, systemic inflammatory symptoms, and difficulties with conception. Despite extensive hematological and rheumatological evaluation, no unifying diagnosis was identified. Imaging ultimately revealed a right frontal dural-based mass initially suspected to represent meningioma. She underwent gross-total resection, and pathological analysis demonstrated a high-grade sarcoma with EWSR1::CREM fusion. Notably, her systemic symptoms resolved completely following tumor removal, and the patient conceived approximately 1 month after resection. LESSONS: This case illustrates a rare intracranial EWSR1::CREM -fused tumor presenting with a paraneoplastic inflammatory syndrome that may have impaired conception in a reproduction-aged female. These lesions can radiographically mimic benign dural-based tumors such as meningioma while producing systemic inflammatory effects. Accurate diagnosis is critical, as tumor-directed therapy may result in resolution of both systemic symptoms and associated reproductive dysfunction. https://thejns.org/doi/10.3171/CASE26694
- 31 December 2024
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 44 (12) , 896-897
DPYD and fluoropyrimidines: Using the data as our guide
- 31 December 2024
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 44 (12) , 896-897
DPYD and fluoropyrimidines: Using the data as our guide
- 1 August 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 19 (8) , 679-680
Pharmacist-Driven Precision Medicine: A Ferry to Cross the Chasm of Interpreting Biomarker Testing Reports
Pharmacists as molecular oncology subspecialists can be integral to the multidisciplinary precision oncology team.
- 1 August 2023
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 19 (8) , 679-680
Pharmacist-Driven Precision Medicine: A Ferry to Cross the Chasm of Interpreting Biomarker Testing Reports
Pharmacists as molecular oncology subspecialists can be integral to the multidisciplinary precision oncology team.
- 20 May 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (15) , 2701-2705
DPYD Testing: Time to Put Patient Safety First
- 20 May 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (15) , 2701-2705
DPYD Testing: Time to Put Patient Safety First
- Open Access
- 25 October 2022
- Published by Springer Nature in Cureus
- Vol. 14 (10) , e30718
A Malignant Glomus Tumor of the Liver Harboring MIR143-NOTCH2 Rearrangement: From Diagnosis to Management
A primary malignant glomus tumor of the liver is extremely rare and diagnostically challenging. We present an exceptional case of such with a diagnosis confirmed by MIR143-NOTCH2 rearrangement. The case was successfully managed with neoadjuvant chemotherapy followed by surgery. This report highlights the utilization of molecular analysis to aid in the diagnosis of rare soft tissue malignancies and supports a multimodality approach to the treatment of large, high-grade malignant glomus tumors.
- 25 October 2022
- Published by Springer Nature in Cureus
- Vol. 14 (10) , e30718
Open AccessA Malignant Glomus Tumor of the Liver Harboring MIR143-NOTCH2 Rearrangement: From Diagnosis to Management
A primary malignant glomus tumor of the liver is extremely rare and diagnostically challenging. We present an exceptional case of such with a diagnosis confirmed by MIR143-NOTCH2 rearrangement. The case was successfully managed with neoadjuvant chemotherapy followed by surgery. This report highlights the utilization of molecular analysis to aid in the diagnosis of rare soft tissue malignancies and supports a multimodality approach to the treatment of large, high-grade malignant glomus tumors.
- 1 August 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (8) , 545-554
Human Epidermal Growth Factor Receptor 2–Targeting Approaches for Colorectal Cancer: Clinical Implications of Novel Treatments and Future Therapeutic Avenues
The treatment paradigm for colorectal cancer (CRC) has changed significantly over the past decade with targeted therapeutics. Human epidermal growth factor receptor 2 ( HER2) amplification is seen among 3%-4% of patients with metastatic CRC (mCRC). The biological discovery of HER2 amplification in cancer cells has led to practice-changing drug development for several solid tumors, including breast, gastric, and esophageal cancers. HER2 amplification is now highly actionable in CRC with distinct therapeutic combinations, including the combination of monoclonal antibodies and HER2 receptor–specific tyrosine kinase inhibitors, as well as antibody-drug conjugates, that delivers targeted cytotoxic agents. However, it is essential to define the therapeutic role and sequence of these different combinations, some of which are already part of standard clinical practice. In this review article, we discuss recent clinical studies demonstrating the clinical benefits of each distinct therapeutic approach and their impacts on the current management of HER2-amplified mCRC. We also review ongoing clinical trials targeting the HER2 pathway in mCRC and elaborate on novel therapeutic opportunities in this space that may further define the changing paradigm of HER2-targeted therapy for CRC.
- 1 August 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 18 (8) , 545-554
Human Epidermal Growth Factor Receptor 2–Targeting Approaches for Colorectal Cancer: Clinical Implications of Novel Treatments and Future Therapeutic Avenues
The treatment paradigm for colorectal cancer (CRC) has changed significantly over the past decade with targeted therapeutics. Human epidermal growth factor receptor 2 ( HER2) amplification is seen among 3%-4% of patients with metastatic CRC (mCRC). The biological discovery of HER2 amplification in cancer cells has led to practice-changing drug development for several solid tumors, including breast, gastric, and esophageal cancers. HER2 amplification is now highly actionable in CRC with distinct therapeutic combinations, including the combination of monoclonal antibodies and HER2 receptor–specific tyrosine kinase inhibitors, as well as antibody-drug conjugates, that delivers targeted cytotoxic agents. However, it is essential to define the therapeutic role and sequence of these different combinations, some of which are already part of standard clinical practice. In this review article, we discuss recent clinical studies demonstrating the clinical benefits of each distinct therapeutic approach and their impacts on the current management of HER2-amplified mCRC. We also review ongoing clinical trials targeting the HER2 pathway in mCRC and elaborate on novel therapeutic opportunities in this space that may further define the changing paradigm of HER2-targeted therapy for CRC.
- 28 June 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 172, 158-170
Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review
- 28 June 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 172, 158-170
Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review
- 4 March 2022
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 45 (4) , 137-141
Core Homologous Recombination Mutations and Improved Survival in Nonpancreatic GI Cancers
Introduction: Homologous recombination mutations (HRM) have led to increased responses to platinum chemotherapy in pancreatic cancer. However, HRMs’ role in nonpancreatic gastrointestinal (GI) cancers remains to be determined. Our objective was to evaluate the prognostic and predictive role of core (BRCA1, BRCA2, PALB2) and noncore HRM in nonpancreatic GI cancers receiving platinum therapy. Materials and Methods: This study performed at Moffitt Cancer Center included metastatic nonpancreatic GI cancer patients treated with platinum therapy. All patients had either a core or noncore HRM, determined by next generation sequencing. Response rates, median progression-free survival (PFS), and median overall survival (OS) were determined and compared between core versus noncore HRM patients. Results: In the study, 69 patients with one or more HRM were included: 63.8% were male, 87.0% were Caucasian, and 47.9% had colorectal cancer. Twenty-one (30.4%) patients had a core HRM and 48 (69.6%) had a noncore HRM. Among evaluable patients (n=64), there was no significant difference in objective response: 20.0% with core HRM versus 22.7% with noncore HRM responded to platinum therapy (P=0.53). Median PFS was 10.4 months versus 7.1 months for core HRM versus noncore HRM, respectively (P=0.039). Median OS was 68.9 months versus 24.3 months (P=0.026) for core HRM versus noncore HRM, respectively. Conclusions: Our study demonstrated response of core and noncore HRM to platinum therapy in metastatic nonpancreatic GI malignancies, suggesting benefit in both groups. Core HRM patients had significantly increased median OS and median PFS compared with those with noncore HRM, suggesting potential prognostic and predictive significance. Larger prospective studies are needed to confirm our findings.
- 4 March 2022
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 45 (4) , 137-141
Core Homologous Recombination Mutations and Improved Survival in Nonpancreatic GI Cancers
Introduction: Homologous recombination mutations (HRM) have led to increased responses to platinum chemotherapy in pancreatic cancer. However, HRMs’ role in nonpancreatic gastrointestinal (GI) cancers remains to be determined. Our objective was to evaluate the prognostic and predictive role of core (BRCA1, BRCA2, PALB2) and noncore HRM in nonpancreatic GI cancers receiving platinum therapy. Materials and Methods: This study performed at Moffitt Cancer Center included metastatic nonpancreatic GI cancer patients treated with platinum therapy. All patients had either a core or noncore HRM, determined by next generation sequencing. Response rates, median progression-free survival (PFS), and median overall survival (OS) were determined and compared between core versus noncore HRM patients. Results: In the study, 69 patients with one or more HRM were included: 63.8% were male, 87.0% were Caucasian, and 47.9% had colorectal cancer. Twenty-one (30.4%) patients had a core HRM and 48 (69.6%) had a noncore HRM. Among evaluable patients (n=64), there was no significant difference in objective response: 20.0% with core HRM versus 22.7% with noncore HRM responded to platinum therapy (P=0.53). Median PFS was 10.4 months versus 7.1 months for core HRM versus noncore HRM, respectively (P=0.039). Median OS was 68.9 months versus 24.3 months (P=0.026) for core HRM versus noncore HRM, respectively. Conclusions: Our study demonstrated response of core and noncore HRM to platinum therapy in metastatic nonpancreatic GI malignancies, suggesting benefit in both groups. Core HRM patients had significantly increased median OS and median PFS compared with those with noncore HRM, suggesting potential prognostic and predictive significance. Larger prospective studies are needed to confirm our findings.
- 16 May 2021
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 4 (5) , 652-658
The pharmacist's responsibility to ensure appropriate use of direct‐to‐consumer genetic testing
Millions of consumers have chosen to pursue direct‐to‐consumer (DTC) genetic testing for personal health‐related and/or non‐health‐related information. However, genetic test results can be complex to interpret, and the regulatory landscape for DTC genetic tests is in flux. Given that these tests are easily accessible and may have implications for health, pharmacists need to be prepared to provide patient education on DTC genetic testing, particularly when the results may provide valuable insights into optimal pharmacotherapy. Pharmacists, regardless of practice site and specialty, are well positioned to provide patient education on the benefits, risks, and limitations of DTC pharmacogenomic tests in clinical practice and to advise patients about pursuing confirmatory clinical testing. This report highlights the responsibility of the pharmacist in the appropriate use of DTC genetic testing, particularly pharmacogenomic testing, using a patient case example across varied health settings.
- 16 May 2021
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 4 (5) , 652-658
The pharmacist's responsibility to ensure appropriate use of direct‐to‐consumer genetic testing
Millions of consumers have chosen to pursue direct‐to‐consumer (DTC) genetic testing for personal health‐related and/or non‐health‐related information. However, genetic test results can be complex to interpret, and the regulatory landscape for DTC genetic tests is in flux. Given that these tests are easily accessible and may have implications for health, pharmacists need to be prepared to provide patient education on DTC genetic testing, particularly when the results may provide valuable insights into optimal pharmacotherapy. Pharmacists, regardless of practice site and specialty, are well positioned to provide patient education on the benefits, risks, and limitations of DTC pharmacogenomic tests in clinical practice and to advise patients about pursuing confirmatory clinical testing. This report highlights the responsibility of the pharmacist in the appropriate use of DTC genetic testing, particularly pharmacogenomic testing, using a patient case example across varied health settings.